PATENT CLAIM ANALYSIS

Application Number: 16364114
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["546", "153000"]

Abstract:
The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.

Claim (Index 12):
A pharmaceutical composition, said pharmaceutical composition comprises a therapeutically effective amount of crystalline Form M according to  claim 1  and pharmaceutically acceptable carriers, diluents or excipients.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 99.0
- Lexical Diversity: 1.83673
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15575352', '16079764', '15579881', '15542597', '16304280']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7899277710766067
- 35 USC 102 Novelty (BERT): 0.6105478338479021
- Combined Prediction Score: 0.7719897773537363
- Mean Citation Score: 397.33679
- Max Citation Score: 540.2833
- Similarity Product: 493.4776631776929

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test